162 related articles for article (PubMed ID: 8267889)
1. Rapid resolution of visual abnormalities with medical therapy alone in patients with large prolactinomas.
Mbanya JC; Mendelow AD; Crawford PJ; Hall K; Dewar JH; Kendall-Taylor P
Br J Neurosurg; 1993; 7(5):519-27. PubMed ID: 8267889
[TBL] [Abstract][Full Text] [Related]
2. Prolactinomas and optic nerve compression: disappearance of suprasellar extension and visual recovery after two weeks bromocriptine treatment.
Woodhouse NJ; Khouqueer F; Sieck JO
Horm Res; 1981; 14(3):141-7. PubMed ID: 7286886
[TBL] [Abstract][Full Text] [Related]
3. Optic chiasmal herniation--an under recognized complication of dopamine agonist therapy for macroprolactinoma.
Jones SE; James RA; Hall K; Kendall-Taylor P
Clin Endocrinol (Oxf); 2000 Oct; 53(4):529-34. PubMed ID: 11012580
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas presenting as primary amenorrhoea and delayed or arrested puberty: response to medical therapy.
Howlett TA; Wass JA; Grossman A; Plowman PN; Charlesworth M; Touzel R; Rees LH; Savage MO; Besser GM
Clin Endocrinol (Oxf); 1989 Feb; 30(2):131-40. PubMed ID: 2612015
[TBL] [Abstract][Full Text] [Related]
5. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
6. Rapid regression of pituitary tumours during bromocriptine treatment of women with hyperprolactinaemia.
Bergh T; Nillius SJ; Lundberg PO; Moström U; Enoksson P; Ohman L; Wide L
Ups J Med Sci; 1982; 87(3):259-67. PubMed ID: 7157557
[TBL] [Abstract][Full Text] [Related]
7. Rapid resolution of visual field defects and reduction in macroprolactinoma size with bromocriptine therapy. A case report.
Kahn SE; Miller JL
S Afr Med J; 1982 Oct; 62(19):696-9. PubMed ID: 7135127
[TBL] [Abstract][Full Text] [Related]
8. Visual function improvement in patients with macroprolactinomas treated with bromocriptine.
Lesser RL; Zheutlin JD; Boghen D; Odel JG; Robbins RJ
Am J Ophthalmol; 1990 May; 109(5):535-43. PubMed ID: 2333917
[TBL] [Abstract][Full Text] [Related]
9. Positive prolactin response to bromocriptine in 2 patients with cabergoline-resistant prolactinomas.
Iyer P; Molitch ME
Endocr Pract; 2011; 17(3):e55-8. PubMed ID: 21324816
[TBL] [Abstract][Full Text] [Related]
10. Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports.
Crosignani P; Ferrari C; Mattei AM
Br J Obstet Gynaecol; 1984 Aug; 91(8):821-3. PubMed ID: 6466586
[No Abstract] [Full Text] [Related]
11. Rapid and long-lasting suppression of prolactin secretion and shrinkage of prolactinomas after injection of long-acting repeatable form of bromocriptine (Parlodel LAR).
Schettini G; Lombardi G; Merola B; Colao A; Miletto P; Caruso E; Lancranjan I
Clin Endocrinol (Oxf); 1990 Aug; 33(2):161-9. PubMed ID: 2225475
[TBL] [Abstract][Full Text] [Related]
12. A case of large prolactinoma supposed to be cured by bromocriptine therapy.
Arita K; Uozumi T; Ohta M
Endocrinol Jpn; 1988 Jun; 35(3):503-9. PubMed ID: 3197661
[TBL] [Abstract][Full Text] [Related]
13. [Treatment of prolactin-secreting pituitary tumors with bromocriptine].
Katzir D; Rosenberg T; Ramot Y; Gaver-Shavit A; Gilboa Y
Harefuah; 1990 Feb; 118(3):141-5. PubMed ID: 2341064
[TBL] [Abstract][Full Text] [Related]
14. Giant prolactinomas in men: efficacy of cabergoline treatment.
Corsello SM; Ubertini G; Altomare M; Lovicu RM; Migneco MG; Rota CA; Colosimo C
Clin Endocrinol (Oxf); 2003 May; 58(5):662-70. PubMed ID: 12699451
[TBL] [Abstract][Full Text] [Related]
15. Effects of long-term treatment with bromocriptine on pituitary prolactinoma in a male.
Ayalon D; Eckstein N; Homonnai ZT; Paz GF; Eshel A; Reider I
Int J Gynaecol Obstet; 1982 Dec; 20(6):481-5. PubMed ID: 6130996
[TBL] [Abstract][Full Text] [Related]
16. Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension.
van 't Verlaat JW; Croughs RJ; Hendriks MJ; Bosma NJ
Can J Neurol Sci; 1990 Feb; 17(1):71-3. PubMed ID: 2311021
[TBL] [Abstract][Full Text] [Related]
17. Growth of prolactinoma despite lowering of serum prolactin by bromocriptine.
Kupersmith MJ; Kleinberg D; Warren FA; Budzilovitch G; Cooper P
Neurosurgery; 1989 Mar; 24(3):417-23. PubMed ID: 2927618
[TBL] [Abstract][Full Text] [Related]
18. Effect of the new dopaminergic agonist CV 205-502 on plasma prolactin levels and tumour size in bromocriptine-resistant prolactinomas.
Duranteau L; Chanson P; Lavoinne A; Horlait S; Lubetzki J; Kuhn JM
Clin Endocrinol (Oxf); 1991 Jan; 34(1):25-9. PubMed ID: 1672268
[TBL] [Abstract][Full Text] [Related]
19. Rapid decompression of anterior intracranial visual pathways with bromocriptine.
Grimson BS; Bowman ZL
Arch Ophthalmol; 1983 Apr; 101(4):604-6. PubMed ID: 6838419
[TBL] [Abstract][Full Text] [Related]
20. Dopamine agonist for the rapid improvement of visual field defects in giant and macro-prolactinomas.
Hacisahinogullari H; Canturk S; Dogansen S; Yarman S
J Fr Ophtalmol; 2022 May; 45(5):511-518. PubMed ID: 35272874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
